BAVARIAN NORDIC/S (OTCMKTS:BVNRY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday. The firm currently has a $8.75 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 15.13% from the company’s current price.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Shares of BVNRY opened at $7.60 on Monday. The company has a quick ratio of 5.07, a current ratio of 5.35 and a debt-to-equity ratio of 0.18. The stock has a market cap of $738.61 million, a price-to-earnings ratio of 26.21 and a beta of 0.78. BAVARIAN NORDIC/S has a 12-month low of $5.92 and a 12-month high of $14.00.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last announced its earnings results on Friday, November 9th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.19. The company had revenue of $34.58 million during the quarter. BAVARIAN NORDIC/S had a negative net margin of 126.80% and a negative return on equity of 19.17%. As a group, research analysts anticipate that BAVARIAN NORDIC/S will post -0.55 earnings per share for the current year.

About BAVARIAN NORDIC/S

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Featured Article: What is the balance sheet?

Get a free copy of the Zacks research report on BAVARIAN NORDIC/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.